Healthcare data analytics company Health Catalyst (NASDAQ: HCAT) beat Wall Street’s revenue expectations in Q3 2026, but sales fell by 26.3% year on year to $56.28 million. The company expects the full year’s revenue to be around $247.5 million, close to analysts’ estimates. Its non-GAAP loss of $0.03 per share was $0.02 above analysts’ consensus estimates.

Is now the time to buy HCAT? Find out in our full research report (it’s free for active Edge members).

StockStory’s take

Health Catalyst’s third quarter performance was shaped primarily by ongoing client churn and the company’s efforts to realign costs through its Project Nexus initiative. President and CEO Simeon Kohl, who joined in September, acknowledged that higher-than-desired client attrition remains a core challenge, stating retention is the “most immediate focus.” He also pointed to the benefits of recent operational changes, including the Vitalware divestiture and the company’s strengthened balance sheet, which now features no debt and $79 million in cash. Management noted that a simpler organizational structure and sharper focus on core solutions are central to addressing persistent margin and service delivery pressures.

Looking ahead, Health Catalyst’s guidance reflects a focus on stabilizing its client base and investing selectively in growth areas that support durable, profitable revenue. Management believes that simplifying the portfolio, prioritizing client needs, and improving execution are critical for future success. CEO Simeon Kohl emphasized, “Retention is foundational to everything else we want to accomplish,” and signaled that migration-related churn pressures will persist through at least the end of 2027. The company expects continued cost discipline and refined resource allocation to underpin its push for sustainable, long-term growth.

Key insights from management’s remarks

Health Catalyst’s leadership emphasized operational changes, client retention, and cost discipline as key levers influencing recent performance and future priorities.

• Client retention as top priority: CEO Simeon Kohl identified higher-than-expected client churn as the most urgent priority, noting that retaining existing customers is necessary to build sustainable, profitable growth. Management is actively engaging with clients to understand and address sources of dissatisfaction, especially as health systems seek more value from existing technology investments.
• Cost structure realignment: The Project Nexus initiative, focused on fundamentally transforming Health Catalyst’s operating model, continued to progress during the quarter. Management is scrutinizing cost alignment to match the current revenue base and is shifting investment toward areas that generate attractive returns, while cutting back on less profitable business lines and contracts.
• Product and portfolio simplification: Leadership outlined the need to reduce operational complexity and make Health Catalyst’s offerings easier for clients to understand and deploy. By simplifying the product suite and integrating acquired capabilities, the company aims to lower barriers to adoption and encourage deeper client relationships.
• Financial foundation strengthened: Following the divestiture of Vitalware and the retirement of the company’s credit facility, Health Catalyst is now debt-free with a cash balance of $79 million. This improved financial flexibility is intended to support targeted investments and strategic execution.
• Margin and service delivery pressures: Adjusted professional services margin was notably impacted by revenue declines and higher internal medical claims costs, which management anticipated in the second half of the year. Steps are being taken to align delivery costs with contract volumes and to manage expenses more effectively moving forward.

Drivers of future performance

Management’s outlook centers on stabilizing client relationships, continued portfolio simplification, and disciplined cost management to support margin improvement and future growth.

• Retention strategy execution: The company is prioritizing early client engagement ahead of renewals, focusing on understanding evolving client needs and delivering measurable value. Management expects that reducing churn will make revenue more predictable and support a gradual return to growth, though migration-related headwinds are expected to persist into the next two years.
• Sharper resource allocation: Investments are being redirected toward product areas and customer segments with the highest potential for durable, profitable revenue. The company is deliberately exiting unprofitable contracts and streamlining operations, with management highlighting that these actions are required to build a more sustainable business model.
• Margin stabilization focus: Ongoing efforts to simplify the operating model and align costs with revenue are anticipated to support margin improvement. Management cautioned that elevated internal benefit costs and the full impact of the Vitalware divestiture will continue to affect near-term profitability, but believes that cost discipline and improved execution can lay the groundwork for long-term margin expansion.

Catalysts in upcoming quarters

Looking forward, the StockStory team will be monitoring (1) progress on reducing client churn and evidence that retention initiatives are translating into more predictable revenue, (2) the pace and impact of operational simplification and resource reallocation under Project Nexus, and (3) trends in professional services margins as the company aligns delivery costs with contract volumes. Updates on new client wins and early indicators of improved commercial effectiveness will also be important to track.

Health Catalyst currently trades at $1.50, in line with $1.51 just before the earnings. In the wake of this quarter, is it a buy or sell? Find out in our full research report (it’s free).

Our favorite stocks right now

ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.

Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+271% between June 2020 and June 2025). Find your next big winner with StockStory today.